MegaPro Biomedical Co., Ltd
6827
Rank in Stocks
#24095
MegaPro Biomedical Co., Ltd. operates as a biotechnology enterprise primarily... MegaPro Biomedical Co., Ltd. operates as a biotechnology enterprise primarily focused on pioneering nanodrugs. Its innovative development pipeline includes MPB-1523, an IOP injection currently in Phase II clinical evaluation for addressing hepatocellular carcinoma. Simultaneously, MPB-1514, an iron injection, is also undergoing Phase II clinical trials, targeting iron deficiency anemia. Furthermore, the firm is advancing MPB-1734, an anti-cancer pharmaceutical, which is in preclinical assessment for the treatment of malignant tumors. Established in 2014, this company is headquartered in Zhubei, Taiwan.
Share Price
$0.45574266
Last synced: 2026-11-10
Market Cap
$36.09M
Change (1 day)
-1.97%
Change (1 year)
-9.45%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MegaPro Biomedical Co., Ltd (6827)
Category
Healthcare
Operating Margin for MegaPro Biomedical Co., Ltd (6827)
Operating Margin as of November 2026 TTM: 0.00%
According to MegaPro Biomedical Co., Ltd's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for MegaPro Biomedical Co., Ltd from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -1,287,092.86% | 64.91% |
| 2023 | -780,483.33% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -2,010.08% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about MegaPro Biomedical Co., Ltd's operating margin
What was MegaPro Biomedical Co., Ltd's operating margin in 2025?
In 2025, MegaPro Biomedical Co., Ltd's operating margin was 0.00%, compared with -1,287,092.86% in 2024.
How has MegaPro Biomedical Co., Ltd's operating margin changed since 2020?
From 2020 to 2025, MegaPro Biomedical Co., Ltd's operating margin was highest in 2025 (0.00%) and lowest in 2024 (-1,287,092.86%).
How does MegaPro Biomedical Co., Ltd's operating margin compare with similar companies?
MegaPro Biomedical Co., Ltd's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.